Expertise in
21
conditions

Dr. David G. Maloney

Internal Medicine
Fred Hutchinson Cancer Center
1100 Fairview Ave N, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
Fred Hutchinson Cancer Center
1100 Fairview Ave N, 
Seattle, WA 

Overview

David Maloney is a primary care provider, practicing in Internal Medicine in Seattle, Washington.

Dr. Maloney is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), B-Cell Lymphoma, and Chronic B-Cell Leukemia (CBCL).

He is actively involved in clinical research, co-authoring 198 peer reviewed articles and participating in 7 clinical trials. Dr. Maloney is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in WA

Languages Spoken

English
Castilian
German
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

Fred Hutchinson Cancer Center
1100 Fairview Ave N, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Biological
Study Drug: JCAR017 (Lisocabtagene Maraleucel) 
Study Phase: Phase 1
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Enrollment Status: Terminated
Publish Date: August 31, 2022
Intervention Type: Other, Biological
Study Drug: ROR1 CAR-Specific T Lymphocytes
Study Phase: Phase 1
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Biological
Study Drug: CD19CAR-4-1BB-CD3zeta-EGFRt CAR-T Cells
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

198 Total Publications

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
Similar Doctors
Expertise in
12
conditions
Dr. David C. Dale
Internal Medicine
Expertise in
12
conditions
Dr. David C. Dale
Internal Medicine

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-543-7215
Languages Spoken:
English, Danish, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

David Dale is a primary care provider, practicing in Internal Medicine in Seattle, Washington. Dr. Dale is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Chronic Familial Neutropenia, Cyclic Neutropenia, and Infantile Neutropenia. Dr. Dale is currently accepting new patients.

Expertise in
22
conditions
Dr. Bruce M. Psaty
Internal Medicine
Expertise in
22
conditions
Dr. Bruce M. Psaty
Internal Medicine

Uw Medicine/Harborview Medical Center

325 9th Ave, 
Seattle, WA 
 (1.7 miles away)
206-520-5000
Languages Spoken:
English, Hindi, Polish, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Bruce Psaty is a primary care provider, practicing in Internal Medicine in Seattle, Washington. Dr. Psaty is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Atherosclerosis, Rhabdomyolysis, Coronary Heart Disease, Heart Failure, and Hormone Replacement Therapy (HRT). Dr. Psaty is currently accepting new patients.

Expertise in
13
conditions
Dr. David S. Siscovick
Internal Medicine
Expertise in
13
conditions
Dr. David S. Siscovick
Internal Medicine

Limited To Univ Of WA Med Facilities Onl

325 9th Ave, 
Seattle, WA 
 (1.7 miles away)
206-731-3000
Languages Spoken:
English
See accepted insurances

David Siscovick is a primary care provider, practicing in Internal Medicine in Seattle, Washington. Dr. Siscovick is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Atherosclerosis, Cardiac Arrest, Type 2 Diabetes (T2D), and Coronary Heart Disease.

Frequently Asked Questions about Dr. David G. Maloney

How do I make an appointment with Dr. David G. Maloney?

You can book an appointment with Dr. David G. Maloney by calling their office at 206-667-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David G. Maloney a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David G. Maloney is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David G. Maloney specialize in?

While Dr. David G. Maloney is a Internal Medicine, they have specific expertise in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David G. Maloney participate in research or clinical trials?

Yes. Dr. David G. Maloney has published 198 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. David G. Maloney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David G. Maloney accept my insurance?

Dr. David G. Maloney accepts most major insurance plans, including Humana and PacificSource. We recommend calling the office directly at 206-667-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maloney's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile